Folger Nolan Fleming Douglas Capital Management Inc. Has $10.58 Million Holdings in Abbott Laboratories $ABT

Folger Nolan Fleming Douglas Capital Management Inc. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 5.8% during the first quarter, Holdings Channel.com reports. The institutional investor owned 103,015 shares of the healthcare product maker’s stock after purchasing an additional 5,637 shares during the period. Abbott Laboratories accounts for 0.9% of Folger Nolan Fleming Douglas Capital Management Inc.’s investment portfolio, making the stock its 29th largest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Abbott Laboratories were worth $10,577,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Freemont Management S.A. raised its stake in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after buying an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $116,580,000. Thrivent Financial for Lutherans increased its holdings in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in Abbott Laboratories in the 3rd quarter valued at $185,640,000. Finally, Net Worth Advisory Group bought a new stake in Abbott Laboratories in the 4th quarter valued at $1,366,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.4%

Shares of Abbott Laboratories stock opened at $92.78 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a 50-day moving average of $89.03 and a 200-day moving average of $105.07. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a market cap of $161.60 billion, a PE ratio of 25.99, a PEG ratio of 1.62 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Monday, June 22nd. Citigroup dropped their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Sanford C. Bernstein decreased their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Barclays lowered their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The U.S. Justice Department reportedly closed its criminal probe into Abbott’s baby formula operations and chose not to pursue criminal charges, which removes a major overhang and reduces the risk of a damaging legal outcome. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Positive Sentiment: Abbott’s Medical Devices business is being positioned for another growth phase, with new diabetes, heart rhythm, and electrophysiology products cited as potential drivers ahead of the company’s next earnings update. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: Healthcare stocks were modestly higher late Monday afternoon, but Abbott still lagged peers and underperformed the sector, suggesting the stock’s move was more idiosyncratic than industry-wide. Sector Update: Healthcare Stocks Higher Late Afternoon
• Neutral Sentiment: Market commentary also highlighted Abbott’s baby formula probe being dropped by the DOJ, reinforcing the legal relief narrative, though investors may still wait for clarity on any civil penalties or follow-on costs. Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
• Negative Sentiment: Despite the DOJ news, Abbott’s shares traded lower and underperformed competitors, indicating that investors may be taking profits or focusing on broader concerns around valuation, growth, or lingering legal uncertainty. Abbott Laboratories stock underperforms Monday when compared to competitors

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.